Advancing Medtech Innovation: Why Strategic Support Matters More Than Ever

By Haddletons
March 31, 2026

From medical devices and diagnostics to digital health solutions, innovation in this space is both rapid and highly regulated.

What this means for our clients in this sector is significant opportunity but also complexity.

Recent findings from the CPI report Turning Innovation into Impact reinforce this reality. Drawing on insights from 10 university technology transfer offices and more than 240 SMEs, the report highlights persistent structural challenges that continue to slow the journey from innovation to patient impact—and calls for more coordinated reform across the ecosystem.

The challenge of bringing medtech to market

Medtech innovators often face a unique set of challenges, including:

  • Demonstrating clinical and commercial viability
  • Protecting and leveraging intellectual property
  • Structuring collaborations with research institutions, clinicians, and industry partners
  • Navigating regulatory and NHS adoption pathways
  • Securing and managing funding to support development and scale-up

Each of these elements plays a critical role in determining whether a promising idea successfully reaches patients.

The CPI report underscores several of these barriers. Innovators frequently cite difficulties engaging with the MHRA, which is perceived as under-resourced and challenging to navigate. At the same time, a shortage of later-stage investment, particularly at Series B+, is pushing companies to look overseas for funding, while fragmented NHS procurement pathways continue to slow adoption of new technologies.

Why early strategic advice is critical

Too often, legal and commercial considerations are addressed later in the development process by which point opportunities may have been missed or risks increased.Early, integrated advice enables medtech companies to take a more strategic and joined-up approach from the outset. It supports the development of a robust intellectual property strategy aligned with long-term commercial objectives, helps ensure that collaborative projects and funding arrangements are structured effectively and reduces risk by addressing freedom to operate at an early stage.It also plays a key role in positioning technologies for investment, partnership and ultimately successful adoption. This is especially important in a sector where innovation is inherently collaborative and often dependent on external funding and strategic partnerships

Maximising value and avoiding leakage at scale-up

As medtech companies move from early-stage development towards scale-up and investment, another critical issue emerges: value leakage.

In our experience, businesses that have not adequately prepared for investor scrutiny can find themselves “chipped” on valuation during due diligence. This is often not because the underlying technology lacks merit, but because key legal, governance, HR, commercial or IP issues have not been fully addressed.

At Haddletons, we work closely with clients, often years ahead of investment, to identify and close these gaps early. This may include undertaking detailed IP audits to ensure assets are properly protected and aligned with commercial strategy, as well as reviewing commercial contracts to ensure collaborations strike the right balance of risk and reward.

For many SMEs, resource constraints make it difficult to address all of these areas internally. Our role is to help prioritise what matters most, enabling businesses to present themselves as investment-ready and to maximise value at the point of funding or exit.

How Haddletons supports medtech clients

At Haddletons, we work with clients across the full medtech lifecycle, from early-stage innovators and spin-outs to scaling businesses and global organisations.

Our team brings together legal expertise and a deep understanding of the medtech landscape

This enables us to provide practical, commercially relevant support at every stage of the innovation journey. We advise on protecting, maximising and enforcing intellectual property, structuring and negotiating commercial arrangements such as collaborations, licences and distribution agreements and supporting clients with their funding rounds and shareholder arrangements. In addition we help clients as they expand (and sometimes contract) with their outsourced HR needs . We also offer strategic guidance on market entry and growth, helping clients position their technologies for long-term success. We recognise that no two innovations are the same and we tailor our advice to reflect the specific needs, risks and ambitions of each client.

Supporting innovation in a funding-driven ecosystem

Funding remains a key driver of innovation in the medtech sector, particularly in the transition from early-stage research to clinical application. Accessing funding requires careful planning around IP ownership, collaboration terms and future commercialisation.

However, as highlighted in the CPI report, gaps in later-stage funding and misalignment between innovation and NHS need continue to present challenges.

Ensuring these elements are aligned from the outset can significantly enhance both the success of funding applications and the long-term value of the innovation.

Learn more

For those interested in exploring current funding opportunities, the NIHR Invention for Innovation (i4i) Programme is hosting an upcoming webinar on 15 April 2026 introducing its latest medtech funding call and application process.

NIHR i4i webinar – sign up here

Get in touch

If you are developing a medtech innovation, considering funding opportunities, or looking to strengthen your commercial and IP strategy, our team would be happy to support you.